RE: The evidence is overwhelming7 Feb 2025 00:17
To calculate a potential takeover price for this biotech company, we’ll use the provided data on its oncology drugs and platform. The key steps involve estimating the Net Present Value (NPV) of the pipeline based on peak sales, probability of success (POS), and discounting future cash flows to their present value. Here's how we can approach this:
________________________________________
1. Data Summary
Drug Peak Sales ($BN) POS (%) POS Calculation ($BN) Current Phase Launch Date
SGC 0.4 15% 0.06 Phase 1 2028
Breast Cancer 2 30% 0.6 Phase 1 2030
AVA6103 2 15% 0.3 IND 2032
AVA7100 0.4 15% 0.06 IND 2032
Platform 0.7 15% 0.105 Preclinical N/A
________________________________________
2. Key Assumptions
• Discount Rate: Typically, a discount rate of 10-15% is used for biotech valuations to account for the high risk and time value of money. We’ll use 12% here.
• Probability of Success (POS): This is already provided for each asset.
• Peak Sales: The estimated peak sales are adjusted by the POS to reflect risk.
• Launch Dates: Cash flows are assumed to start in the launch year and grow linearly to peak sales over 3-5 years.
• Platform Valuation: The platform is valued separately, as it may have broader applications beyond the listed drugs.
________________________________________
3. Calculate Risk-Adjusted Peak Sales
Multiply peak sales by the probability of success (POS) for each drug:
Drug Peak Sales ($BN) POS (%) Risk-Adjusted Sales ($BN)
SGC 0.4 15% 0.06
Breast Cancer 2 30% 0.6
AVA6103 2 15% 0.3
AVA7100 0.4 15% 0.06
Platform 0.7 15% 0.105
Total Risk-Adjusted Sales:
0.06+0.6+0.3+0.06+0.105=1.125 BN0.06+0.6+0.3+0.06+0.105=1.125BN
________________________________________
4. Discount Future Cash Flows
To estimate the NPV, we discount the risk-adjusted sales back to the present value using the formula:
NPV=Risk-Adjusted Sales(1+Discount Rate)Years Until LaunchNPV=(1+Discount Rate)Years Until LaunchRisk-Adjusted Sales
Drug Risk-Adjusted Sales ($BN) Launch Year Years Until Launch NPV ($BN)
SGC 0.06 2028 5 0.06(1+0.12)5=0.034(1+0.12)50.06=0.034
Breast Cancer 0.6 2030 7 0.6(1+0.12)7=0.271(1+0.12)70.6=0.271
AVA6103 0.3 2032 9 0.3(1+0.12)9=0.108(1+0.12)90.3=0.108
AVA7100 0.06 2032 9 0.06(1+0.12)9=0.022(1+0.12)90.06=0.022
Platform 0.105 N/A N/A 0.105
Total NPV:
0.034+0.271+0.108+0.022+0.105=0.54 BN0.034+0.271+0.108+0.022+0.105=0.54BN
________________________________________
5. Adjust for Platform Value
The platform’s value is already included in the NPV calculation. However, if the platform has additional strategic value (e.g., partnerships, licensing potential), it could warrant a premium.
________________________________________
6. Final Takeover Price
The estimated NPV of the pipeline is $540 million. However, in a takeover scenario, acquirers often pay a premium (e.g., 30-100%) to secure the assets. Assuming a 50% premium:
Takeover Price=540 M×1.5=810 M
Takeover Price=540M×1.5=810M
Sign In
Follow the stocks
